Current state and limitations of daily oral therapy for treatment

被引:32
作者
Solomon, Daniel A. [1 ]
Sax, Paul E. [1 ]
机构
[1] Brigham & Womens Hosp, Div Infect Dis, Boston, MA 02130 USA
关键词
antiretroviral; HIV; limitations; oral; strengths; HIV-INFECTED PATIENTS; ANTIRETROVIRAL THERAPY; COST-EFFECTIVENESS; DISEASE RISK; TENOFOVIR; INFLAMMATION; COAGULATION; PREVENTION; INHIBITORS; LAMIVUDINE;
D O I
10.1097/COH.0000000000000165
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Purpose of reviewWe aim to review the strengths and weaknesses of current antiretroviral therapy (ART), and describe ongoing research to address limitations to current therapy.Recent findingsCurrent ART is highly effective and well tolerated. As a result of a decrease in medication side-effects and pill burden, and the known health effects of uncontrolled viremia, ART is now recommended at all CD4 cell counts in the USA. Novel medications are being developed to further decrease side-effects and offer alternative options for patients with multiclass resistance. New combination pills will further decrease pill burden.SummaryCurrent treatment for HIV is characterized by highly potent oral antiretroviral medications, which are well tolerated, resulting in outstanding rates of virologic suppression in patients who are adherent to therapy. Despite the marked improvement in therapeutic options, limitations to therapy still exist including reliance on daily adherence, long-term toxicity of medications, drug-drug interactions, long-term effects of HIV even in the setting of viral suppression, high lifetime cost of treatment, and limited options for some patients with multiclass resistance. Emerging alternative treatment strategies include nucleoside reverse transcriptase inhibitor-sparing or limiting regimens and long-acting injectable combination therapy.
引用
收藏
页码:219 / 225
页数:7
相关论文
共 50 条
[31]   Current Scenario of HIV/AIDS, Treatment Options, and Major Challenges with Compliance to Antiretroviral Therapy [J].
Bhatti, Adnan Bashir ;
Usman, Muhammad ;
Kandi, Venkataramana .
CUREUS, 2016, 8 (03)
[32]   Current Treatment Strategies, Complications and Considerations for the Use of HIV Antiretroviral Therapy during Pregnancy [J].
Senise, Jorge F. ;
Castelo, Adauto ;
Martinez, Marisol .
AIDS REVIEWS, 2011, 13 (04) :198-213
[33]   The Current State of Biologic Therapies for Treatment of Refractory Asthma [J].
Mavissakalian, Matthew ;
Brady, Sean .
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2020, 59 (02) :195-207
[34]   Current pharmacotherapy for the treatment of dyslipidemia associated with HIV infection [J].
Gebhardt, Anna ;
Fichtenbaum, Carl J. .
EXPERT OPINION ON PHARMACOTHERAPY, 2019, 20 (14) :1719-1729
[35]   Overview of the Current State of the Epidemic [J].
Hankins, Catherine .
CURRENT HIV/AIDS REPORTS, 2013, 10 (02) :113-123
[36]   Anti-inflammatory Drugs and Prostatic Carcinoma: Current State of Evidence [J].
Schmid, H. -P. ;
Engeler, D. S. ;
Theiler, R. .
AKTUELLE UROLOGIE, 2012, 43 (02) :112-114
[37]   Photobiomodulation and photodynamic therapy for the treatment of oral mucositis in patients with cancer [J].
Pires Marques, Erika Cristina ;
Lopes, Felipe Piccolo ;
Nascimento, Ingrid Camargo ;
Morelli, Juliana ;
Pereira, Milena Valini ;
Machado Meiken, Vitoria Moron ;
Pinheiro, Sergio Luiz .
PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY, 2020, 29
[38]   Evaluation of treatment efficacy after switching to dolutegravir-lamivudine dual therapy in people living with HIV [J].
Ergen, Pinar ;
Bektas, Beguem ;
Aydin, Oezlem ;
Keskin, Havva ;
uecisik, Ayse Canan ;
Karadag, Fatma Yilmaz ;
Cag, Yasemin .
AFRICAN HEALTH SCIENCES, 2022, 22 (03) :426-435
[39]   Current Status and Prospect of Prevention and Treatment of Oral Diseases by Integrative Medicine [J].
徐治鸿 .
Chinese Journal of Integrated Traditional and Western Medicine, 2006, (04) :241-243
[40]   Review of current clinical experience with prolonged (oral) etoposide in cancer treatment [J].
DeJong, RS ;
Mulder, NH ;
Dijksterhuis, D ;
DeVries, EGE .
ANTICANCER RESEARCH, 1995, 15 (5B) :2319-2330